Clinical Kidney Journal
Kidney drug showed no clear short-term effect on minerals in urine
In a crossover trial, 15 adults with autosomal dominant polycystic kidney disease took empagliflozin or placebo for 14 days each.In a crossover trial, 15 adults with autosomal dominant polycystic kidney disease took empagliflozin or placebo for 14 days each.

Randomized trial · 15 peopleKidney
Who was studied15 adults with autosomal dominant polycystic kidney disease, against placebo
What changedUrinary minerals did not clearly differ with empagliflozin versus placebo; phosphate differed by +10.8% (95% CI −5.9 to +27.6)
The catchOnly 15 participants completed the study, below 36 planned, limiting detection of smaller effects







